How are U.S. tariffs and Korean biopharma deals fragmenting pharma markets?

The article says three developments point to a more fragmented pharma market: U.S. import tariffs on generic drugmakers, Samsung Biologics pursuing a $1.8 billion acquisition, and a U.S. biotech seeking a Hong Kong-first IPO. Together they suggest increasing divergence in supply chains, financing routes, and strategic dealmaking across the industry.